Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
412.62
Oct 30 • 3:59 PM ET Dollar change-4.05 Percentage change(-0.97%)
Aftermarket Close
412.62
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Oct 29, 11:38 AMWest Pharma beats Q3 with EPS $2.66, revenue $874.5M, raises 2026 guidance on GLP‑1 and HVP strength
Index
S&P 500
Market Cap
28.74B
Enterprise Value
28.59B
Income
638.90M
Sales
3.40B
Book/sh
42.52
Cash/sh
6.66
Employees
10800
IPO
Mar 17, 1980
P/E
46.27
Forward P/E
40.08
PEG
2.27
P/S
8.46
P/B
9.70
P/C
61.93
P/FCF
63.40
EV/EBITDA
29.70
EV/Sales
8.42
Quick Ratio
2.10
Current Ratio
2.82
Debt/Eq
0.11
LT Debt/Eq
0.10
Option/Short
Yes / Yes
EPS (ttm)
8.92
EPS next Y
10.29
EPS next Q
2.29
EPS this Y
29.40%
EPS next Y
9.13%
EPS next 5Y
17.66%
EPS past 3/5Y
-4.22% 8.26%
Sales past 3/5Y
2.14% 7.45%
EPS Y/Y TTM
32.05%
Sales Y/Y TTM
12.60%
EPS Q/Q
56.74%
Sales Q/Q
8.72%
Insider Own
0.75%
Insider Trans
-2.91%
Inst Own
102.97%
Inst Trans
-1.65%
ROA
15.65%
ROE
21.23%
ROIC
19.59%
Gross Margin
37.68%
Oper. Margin
22.92%
Profit Margin
18.81%
SMA20
7.11%
SMA50
12.25%
SMA200
31.67%
Trades
Shs Outstand
69.80M
Shs Float
69.14M
52W High
438.27 -5.85%
52W Low
223.83 84.35%
Volatility
2.95% 2.44%
ATR (14)
10.31
RSI (14)
75.33
Beta
1.15
Rel Volume
1.86
Avg Volume
571.80K
Volume
1,062,356
Perf Week
5.22%
Perf Month
13.04%
Perf Quarter
18.59%
Perf Half Y
37.23%
Perf YTD
49.97%
Perf Year
48.14%
Perf 3Y
29.00%
Perf 5Y
-4.02%
Perf 10Y
462.92%
Prev Close
416.67
Price
412.62
Change %
-0.97%
Consensus
Strong Buy
Avg. Price Target
$474.64
Implied Upside
+15.0%
Analysts13incl. previous ratings
Rating Distribution13 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 22, 2026Upgrade
MS logoMMorgan Stanley
Equal-Weight → Overweight$400-3.1%
Sep 09, 2026Resumed
UBS logoUUBS
Buy$415+0.6%
Jul 13, 2026Initiated
BBNP Paribas Exane
Outperform$447+8.3%
Jun 09, 2026Upgrade
BCS logoBBarclays
Equal Weight → Overweight$400-3.1%
Jun 02, 2026Resumed
WWolfe Research
Outperform$375-9.1%
Dec 02, 2025Initiated
MS logoMMorgan Stanley
Equal-Weight$285-30.9%
Sep 15, 2025Initiated
RRothschild & Co Redburn
Buy$311-24.6%
Jun 24, 2025Initiated
BCS logoBBarclays
Equal Weight$245-40.6%
Mar 18, 2025Initiated
EVR logoEEvercore ISI
Outperform$275-33.4%
Feb 14, 2025Upgrade
DB logoDDeutsche Bank
Hold → Buy$250-39.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Favorite Annette FSr. VP & Chief HR OfficerSep 15 '26Option Exercise89.642,524226,25124,342Sep 15 04:37 PM
Favorite Annette FSr. VP & Chief HR OfficerSep 11 '26Option Exercise89.642,500224,10024,318Sep 15 04:37 PM
Favorite Annette FSr. VP & Chief HR OfficerSep 14 '26Option Exercise89.642,500224,10024,318Sep 15 04:37 PM
Favorite Annette FSr. VP & Chief HR OfficerSep 15 '26Sale365.002,524921,26021,818Sep 15 04:37 PM
Favorite Annette FSr. VP & Chief HR OfficerSep 14 '26Sale355.002,500887,50021,818Sep 15 04:37 PM
Favorite Annette FSr. VP & Chief HR OfficerSep 11 '26Sale345.002,500862,50021,818Sep 15 04:37 PM
Favorite Annette FSr. VP & Chief HR OfficerSep 08 '26Option Exercise85.378,135694,45319,663Sep 10 05:36 PM
Favorite Annette FSr. VP & Chief HR OfficerSep 08 '26Sale340.818,1352,772,48916,845Sep 10 05:36 PM
Hofmann Thomas WDirectorMay 07 '26Proposed Sale322.123,3841,090,051May 07 03:34 PM
Favorite Annette FSr. VP & Chief HR OfficerApr 27 '26Option Exercise83.472,817235,13519,645Apr 29 12:22 PM
Favorite Annette FSr. VP & Chief HR OfficerApr 27 '26Sale305.202,817859,75316,828Apr 29 12:22 PM
Winters ChadVP, Chief Accounting OfficerApr 27 '26Option Exercise173.22896155,2052,419Apr 29 12:19 PM
Winters ChadVP, Chief Accounting OfficerApr 27 '26Sale300.67896269,3991,523Apr 29 12:19 PM
West Pharmaceutical Services, Inc. engages in the design, manufacture, and sale of containment and delivery systems for injectable drugs and healthcare products. It operates through the Proprietary Products and Contract-Manufactured Products segments. The Proprietary Products segment offers proprietary packaging, containment solutions, drug delivery systems, analytical lab services, and other integrated services and solutions, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.
Senior VP & CFOMr. Robert W. McMahon C.M.A.
Chief HR Officer & Senior VPMs. Annette F. Favorite
SVP & Chief Proprietary Segment OfficerMr. Shane A. Campbell
PresidentMr. Michel Lagarde
VP of Finance & Chief Accounting OfficerMr. Chad R. Winters